Instillido

Lidocaine Hydrochloride, the active ingredient in Instillido, is a Local anesthetic presented as a solution for urethral use. It provides temporary loss of sensation to facilitate procedures involving the urethra. GNH USA supplies Instillido as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Lidocaine Hydrochloride is a local anesthetic used for urethral anesthesia.

- Urethral anesthesia: provides temporary loss of sensation to enable pain‑free urethral examinations and interventions. - Urethral catheter insertion: reduces discomfort during catheter placement. - Cystoscopic procedures: facilitates a tolerable environment for bladder inspection via the urethra.

Lidocaine Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Burning or stinging sensation at the application site. - Mild local irritation or redness. - Transient numbness extending beyond the target area. - Urinary urgency or frequency. - Mild headache. - Dizziness.

Serious or Rare Side Effects: - Allergic reaction (rash, swelling, bronchospasm). - Systemic toxicity (seizures, cardiac arrhythmia, hypotension). - Methemoglobinemia. - Severe hypotension. - Anaphylaxis. - Persistent numbness or motor weakness.

Before using Instillido, consider the following safety measures.

- Allergy assessment: confirm no known hypersensitivity to lidocaine or amide‑type anesthetics. - Cardiac history: avoid in patients with significant conduction disorders or severe heart disease. - Liver function: use caution in severe hepatic impairment as metabolism may be reduced. - Concomitant local anesthetics: limit total dose to prevent cumulative toxicity. - Pediatric use: restrict to situations where the benefit outweighs risk and dosing is carefully calculated. - Store below 25°C: keep in the original container, protect from moisture and light.

Lidocaine Hydrochloride can interact with other medications that affect sodium channels or hepatic metabolism.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): increase risk of cardiac toxicity. - Amiodarone: may potentiate lidocaine plasma levels. - Cimetidine: can reduce hepatic clearance, raising systemic exposure.

Moderate Interactions (Monitor Closely): - Other local anesthetics: cumulative dose may lead to systemic toxicity. - Beta‑blockers (e.g., propranolol): may enhance lidocaine's cardiac effects. - CYP3A4 inhibitors (e.g., erythromycin): modestly increase lidocaine concentrations.